Human Patents (Class 530/388.15)
-
Patent number: 8609090Abstract: Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods of detecting the amount of HGF in a sample using a specific binding agent to HGF are described.Type: GrantFiled: July 16, 2004Date of Patent: December 17, 2013Assignees: Amgen Inc., Amgen Fremont Inc.Inventors: Teresa L. Burgess, Angela Coxon, Larry L. Green, Ke Zhang
-
Publication number: 20130330350Abstract: Provided in some embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain. Also provided in certain embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain where the native interchain cysteine amino acids have been replaced by amino acids having no thiol moiety.Type: ApplicationFiled: November 8, 2011Publication date: December 12, 2013Applicant: MedImmune, LLCInventor: Nazzareno Dimasi
-
Patent number: 8604171Abstract: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: GrantFiled: July 27, 2012Date of Patent: December 10, 2013Assignee: Tanox, Inc.Inventors: Sanjaya Singh, Herren Wu, Catherine Foster
-
Patent number: 8603987Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.Type: GrantFiled: October 28, 2011Date of Patent: December 10, 2013Assignee: Galaxy Biotech, LLCInventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
-
Patent number: 8598321Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: GrantFiled: March 21, 2008Date of Patent: December 3, 2013Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Isin N. Geren, Jianlong Lou
-
Patent number: 8597648Abstract: The present invention provides a full human anti-TNF-? monoclonal antibody, the preparation method and use thereof. The antibody in the present invention has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The antibody in the present invention can be used to prepare medicines for the treatment of autoimmune disorders.Type: GrantFiled: April 16, 2010Date of Patent: December 3, 2013Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.Inventors: Huaizu Guo, Chuan Li, Xin Tong
-
Publication number: 20130315921Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.Type: ApplicationFiled: August 5, 2013Publication date: November 28, 2013Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
-
Patent number: 8586041Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: May 11, 2009Date of Patent: November 19, 2013Assignee: Genmab A/SInventors: Jan G. J. van de Winkel, Marcus Antonius van Dijk, Edward Halk, Arnout F. Gerritsen, Jorgen Petersen, Ole Baadsgaard
-
Patent number: 8586042Abstract: The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and “DLFGR.Type: GrantFiled: December 9, 2010Date of Patent: November 19, 2013Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Sunil Kaul
-
Patent number: 8580260Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: December 22, 2010Date of Patent: November 12, 2013Assignee: Novartis AGInventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
-
Patent number: 8580930Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: August 20, 2012Date of Patent: November 12, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
-
Patent number: 8575318Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: August 20, 2012Date of Patent: November 5, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
-
Patent number: 8575316Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: April 7, 2010Date of Patent: November 5, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20130291134Abstract: This invention relates to a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multi-transgenic animal. This invention also relates to methods for screening compositions for human vaccine development. More specifically, the present invention relates to a mouse model capable of expressing human leukocyte antigens DR4 and A2, and/or human costimulatory molecules (CD80) which upon infusion of human HLA-matched hematopoietic stem cells develop a functional human immune system able to respond to vaccination with human vaccines. The invention also relates to method of producing human antibodies specific for a desired antigen using the transgenic mouse.Type: ApplicationFiled: August 22, 2012Publication date: October 31, 2013Inventors: Sofia a. Casares, Tepdpr D. Brumeanu
-
Patent number: 8569242Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.Type: GrantFiled: December 27, 2011Date of Patent: October 29, 2013Assignee: The Regents of the University of CaliforniaInventor: Katerina Akassoglou
-
Patent number: 8569459Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.Type: GrantFiled: May 23, 2012Date of Patent: October 29, 2013Assignee: Medimmune, LLCInventors: David Jenkins, Neil Michaud, Naomi Laing, Jaspal Singh Kang
-
Publication number: 20130280264Abstract: Toll-like receptors (TLR) are expressed by a variety of cancers, including melanoma and T-ALL. TLR signaling plays an important role in T cell malignancies and melanoma. The effects of stimulating or inhibiting the TLR/IL-1 receptor-associated kinases IRAK-1 and IRAK-4 in melanoma and T-ALL cells were evaluated. Pharmacological treatment with an IRAK-1,-4 inhibitor delays tumor growth and prolongs survival in vitro and in vivo, indicating that TLR signaling contributes to T-ALL and melanoma progression and interfering with this signaling is a novel therapeutic strategy to control T-ALL and melanoma proliferation.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Inventor: Eduardo Davila
-
Publication number: 20130280266Abstract: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.Type: ApplicationFiled: April 5, 2013Publication date: October 24, 2013Applicants: BRISTOL-MYERS SQUIBB COMPANY, PFIZER INC.Inventors: Arvind Rajpal, Madhav Narasimha Devalaraja, Kristopher Toy, Lan Yang, Haichun Huang, Jun Z. Zhang, Peter Brams, Brigitte Devaux, David B. Passmore
-
Patent number: 8563695Abstract: Compositions and methods are provided for the classification, diagnosis, treatment, and prevention of tumors characterized by loss of REST function, expression of ?2, and/or activation of Notch. Further compositions and methods are provided for modulation of cellular processes such as EMT, cell migration, and apoptosis.Type: GrantFiled: November 18, 2008Date of Patent: October 22, 2013Assignee: Genentech, Inc.Inventors: Jo-Anne Hongo, Jing Li, Victoria Smith
-
Publication number: 20130274450Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: ApplicationFiled: March 14, 2013Publication date: October 17, 2013Inventors: Olivia RAEBER, Gadi GAZIT-BORNSTEIN, Xiao-Dong YANG, Susan Ann CARTLIDGE, David William TONGE
-
Publication number: 20130266558Abstract: Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. The human or humanized VH framework regions may comprise one or more of the following residues: a valine at position 24 of FW1, a glycine at position 49 of FW2, and an asparagine at position 73 of FW3, numbered according to Kabat. Further provided are pharmaceutical and immunotherapeutic compositions, and methods using anti-CD22 antibodies that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases in humans, including B cell malignancies, autoimmune disease, GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder.Type: ApplicationFiled: February 28, 2013Publication date: October 10, 2013Inventors: Tarran Jones, David G. Williams
-
Patent number: 8551484Abstract: Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: February 13, 2008Date of Patent: October 8, 2013Assignee: University of MassachusettsInventors: Donna M. Ambrosino, William D. Thomas, Jr., Gregory J. Babcock, Teresa Broering, Susan Sloan
-
Patent number: 8551482Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.Type: GrantFiled: May 31, 2012Date of Patent: October 8, 2013Assignee: Novartis AGInventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
-
Publication number: 20130259871Abstract: Compositions and methods for the treatment or prevention of Dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to Dengue virus isolated from EBV immortalized B cells derived from patients who have recovered from Dengue infection are disclosed. Methods are provided for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.Type: ApplicationFiled: December 14, 2011Publication date: October 3, 2013Applicants: DSO NATIONAL LABORATORIES, NATIONAL UNIVERSITY OF SINGAPOREInventors: Paul Anthony Macary, Ee Ping Evelyn Teoh, Brendon John Hanson, En Wei Teo, Angeline Pei Chiew Lim, Mah Lee Mary Ng, Shee Mei Lok, Petra Eveliina Kukkaro
-
Patent number: 8546539Abstract: Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. Also disclosed are molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies) that include a variant CDR3 region, wherein the variant CDR3 region includes at least one amino acid modified relative to a wild-type CDR3 region. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.Type: GrantFiled: May 14, 2008Date of Patent: October 1, 2013Assignee: Novimmune S.A.Inventors: Greg Elson, Olivier Leger
-
Patent number: 8546543Abstract: The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.Type: GrantFiled: October 12, 2011Date of Patent: October 1, 2013Assignee: Xencor, Inc.Inventor: Gregory Alan Lazar
-
Patent number: 8546546Abstract: An antibody that binds to Mucin17 (Muc17) is disclosed. The antibody of the present invention preferably binds to the peptide of SEQ ID NO:3 and does not bind to the peptide of SEQ ID NO:4 or the peptide of SEQ ID NO:5. Also disclosed are an anti-cancer agent, preferably an anti-cancer agent for pancreatic cancer, which comprises the antibody of the present invention, as well as a method of diagnosing cancer using the antibody of the present invention, preferably the antibody of the present invention that does not bind to the secreted-form of Muc17.Type: GrantFiled: July 3, 2008Date of Patent: October 1, 2013Assignee: Forerunner Pharma Research Co., Ltd.Inventor: Kiyotaka Nakano
-
Patent number: 8546545Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.Type: GrantFiled: March 22, 2012Date of Patent: October 1, 2013Assignee: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Publication number: 20130251704Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: January 16, 2013Publication date: September 26, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser.Inventor: The United States of America, as represented by the Secretary, Department of Health and Human Service
-
Publication number: 20130251726Abstract: The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.Type: ApplicationFiled: March 10, 2013Publication date: September 26, 2013Applicants: International AIDS Vaccine Initiative, National Institutes of Health, The Scripps Research InstituteInventors: John Mascola, Dennis R. Burton, Wayne Koff, Peter Kwong, Gary Nabel, Sanjay K. Phogat, Pascal Raymond Georges Poignard, Melissa Danielle De Jean St. Marcel Simek-Lemos, Xueling Wu, Tongqing Zhou, Zhi-Yong Yang
-
Patent number: 8540988Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: GrantFiled: June 2, 2011Date of Patent: September 24, 2013Assignee: Alethia Biotherapeutics Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Patent number: 8541552Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.Type: GrantFiled: February 11, 2011Date of Patent: September 24, 2013Assignee: Genetech, Inc.Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
-
Patent number: 8540986Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.Type: GrantFiled: April 29, 2010Date of Patent: September 24, 2013Assignee: Janssen Biotech, Inc.Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
-
Publication number: 20130243792Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: March 7, 2013Publication date: September 19, 2013Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H.J. Kwaks
-
Patent number: 8536118Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.Type: GrantFiled: September 29, 2009Date of Patent: September 17, 2013Assignee: Genentech, Inc.Inventors: Monica Kong-Beltran, Dineli M. Wickramasinghe
-
Patent number: 8529902Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 17, 2003Date of Patent: September 10, 2013Assignee: Genmab A/SInventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
-
Patent number: 8524230Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.Type: GrantFiled: December 21, 2009Date of Patent: September 3, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver
-
Patent number: 8524867Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.Type: GrantFiled: August 14, 2007Date of Patent: September 3, 2013Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
-
Publication number: 20130224188Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.Type: ApplicationFiled: February 6, 2013Publication date: August 29, 2013Applicant: INHIBRX LLCInventor: InhibRx LLC
-
Patent number: 8518887Abstract: The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.Type: GrantFiled: June 25, 2010Date of Patent: August 27, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Irene Noguera-Troise, Gavin Thurston, Alain Thibault
-
Publication number: 20130216550Abstract: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.Type: ApplicationFiled: September 22, 2011Publication date: August 22, 2013Applicant: IMBA-INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GMBHInventors: Josef Penninger, Daniel Schramek
-
Publication number: 20130216548Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: ApplicationFiled: March 10, 2011Publication date: August 22, 2013Applicant: GENMAB A/SInventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
-
Publication number: 20130216549Abstract: The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-10, CXCL10), thereby modulating the interaction between IP-10 and its receptor, CXCR3, and/or modulating the biological activities of IP-10. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.Type: ApplicationFiled: August 29, 2012Publication date: August 22, 2013Inventors: Nicolas Fischer, Marie Kosco-Vilbois, Olivier Leger
-
Patent number: 8512712Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.Type: GrantFiled: February 29, 2012Date of Patent: August 20, 2013Assignee: Oncolytics Biotech Inc.Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
-
Publication number: 20130209482Abstract: The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.Type: ApplicationFiled: December 15, 2011Publication date: August 15, 2013Applicant: Galaxy Biotech, LLCInventors: Kyung Jin Kim, Lihong Wang, Hangil Park, Maximiliano Vasquez
-
Patent number: 8507657Abstract: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.Type: GrantFiled: August 23, 2012Date of Patent: August 13, 2013Assignee: Morphotek, Inc.Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
-
Patent number: 8507442Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.Type: GrantFiled: June 20, 2011Date of Patent: August 13, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
-
Patent number: 8501173Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: GrantFiled: January 11, 2011Date of Patent: August 6, 2013Assignees: The General Hospital Corporation, The Feinstein Institute for Medical Research, University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
-
Patent number: 8501180Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: January 18, 2011Date of Patent: August 6, 2013Assignee: Kyowa Hakko Kirin Co., LtdInventor: Tsuguo Kubota
-
Publication number: 20130195872Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: NOVIMMUNE S.A.Inventor: NOVIMMUNE S.A.